Literature DB >> 32223138

Mitochondrial-Targeted and Near-Infrared Fluorescence Probe for Bioimaging and Evaluating Monoamine Oxidase A Activity in Hepatic Fibrosis.

Zheng-Min Yang1,2, Qing-Yuan Mo1, Ji-Man He1, Dong-Liang Mo1, Jun Li1, Hua Chen1, Shu-Lin Zhao1, Jiang-Ke Qin1.   

Abstract

Monoamine oxidase A (MAO-A) is a promising diagnostic marker for cancer, depression, Parkinson's disease, and liver disease. The fluorescence detection of MAO-A in living animals is of extreme importance for the early diagnosis of related diseases. However, the development of specific and mitochondrial-targeted and near-infrared (NIR) fluorescence MAO-A probes is still inadequate. Here, we designed and synthesized four NIR fluorescence probes containing a dihydroxanthene (DH) skeleton to detect MAO-A in complex biological systems. The specificity of our representative probe DHMP2 displays a 31-fold fluorescence turn-on in vitro, and it can effectively accumulate in the mitochondria and specifically detect the endogenous MAO-A concentrations in PC-3 and SH-SY5Y cell lines. Furthermore, the probe DHMP2 can be used to visualize the endogenous MAO-A activity in zebrafish and tumor-bearing mice. More importantly, it is the first time that the MAO-A activity of hepatic fibrosis tissues is detected through the probe DHMP2. The present study shows that the synthesized DHMP2 might serve as a potential tool for monitoring MAO-A activity in vivo and diagnosing related diseases.

Entities:  

Keywords:  bioimaging; hepatic fibrosis; mitochondrial-targeted; monoamine oxidase A; near-infrared fluorescence probe

Mesh:

Substances:

Year:  2020        PMID: 32223138     DOI: 10.1021/acssensors.9b02116

Source DB:  PubMed          Journal:  ACS Sens        ISSN: 2379-3694            Impact factor:   7.711


  1 in total

1.  TME-targeting theranostic agent uses NIR tracking for tumor diagnosis and surgical resection and acts as chemotherapeutic showing enhanced efficiency and minimal toxicity.

Authors:  Zhongyuan Xu; Jianqiang Qian; Chi Meng; Yun Liu; Qian Ding; Hongmei Wu; Peng Li; Fansheng Ran; Gong-Qing Liu; Yunyun Wang; Yong Ling
Journal:  Theranostics       Date:  2022-02-28       Impact factor: 11.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.